Prof. Amit Nathwani

Professor Amit Nathwani is a world-renowned British-South Asian physician-scientist and serial biotech entrepreneur. He holds a professorship at University College London, where his research has focused on haematology, immunotherapy, and gene therapy. His work has produced transformative clinical programmes, and he is also the founder of Freeline Therapeutics, a haemophilia gene therapy company in which he remains a board member. He is widely regarded as one of the UK's most accomplished academic-turned-founder figures in life sciences.

In 2018, Nathwani founded NovalGen, a London-headquartered immuno-oncology company built on proprietary intellectual property from UCL. He became CEO and board member in 2021 as the company transitioned to clinical-stage operations. NovalGen's lead programme, NVG-222, is a next-generation bispecific T-cell engager for haematological malignancies, developed with the company's proprietary AutoRegulation technology — designed to make immunotherapy safer by limiting runaway immune activation. In March 2026, the first patient was dosed in a Phase I trial sponsored by Cancer Research UK's Centre for Drug Development.

NovalGen has secured investment from Convergys Capital, UCL Technology Fund, AlbionVC, and UCL Business, raising £1.8 million in its most recent round. The company has partnered with institutions including St. Jude Children's Research Hospital and MD Anderson Cancer Center, cementing its position as one of the UK's most clinically advanced bispecific antibody companies.